Demographics | Patients |
(n=233) | |
Age at diagnosis (years) | |
Mean±SD | 61.1±10.9 |
Median (range) | 61.1 (35.6–85.4) |
Family history (n (%)) | |
Family history documented | 29 (12.4) |
Breast cancer | 19 (8.2) |
Ovarian cancer | 2 (0.9) |
Both | 8 (3.4) |
Data unknown* | 204 (87.6) |
BRCA test (n (%)) | |
BRCA test status unknown | 197 (84.5) |
BRCA status tested | 36 (15) |
BRCA mutation | 18 (7.7) |
No BRCA mutation† | 18 (7.7) |
FIGO stage at diagnosis (n (%)) | |
Stage IA | 0 (0.0) |
Stage IB | 0 (0.0) |
Stage IC | 1 (0.4) |
Stage IIA | 2 (0.9) |
Stage IIB | 4 (1.7) |
Stage IIC | 8 (3.4) |
Stage IIIA | 22 (9.4) |
Stage IIIB | 6 (2.6) |
Stage IIIC | 129 (55.4) |
Stage IV | 38 (16.3) |
Data not recorded (unknown)* | 23 (9.9) |
ECOG performance status (at diagnosis)‡ (n (%)) | |
0 | 40 (17.2) |
1 | 70 (30.0) |
2 | 20 (8.6) |
3 | 1 (0.4) |
4 | 1 (0.4) |
Data not recorded (unknown)§ | 101 (43.3) |
*Data not recorded indicates missing data and negative responses.
†Includes patients with a BRCA variant of unknown significance ‘mutation’.
‡The Eastern Cooperative Oncology Group (ECOG) performance status is measured on a scale from 0 to 4, with 0=normal activity, 1=restricted in strenuous activity but ambulatory and able to carry out light work, 2=ambulatory more than 50% of the time, 3=ambulatory 50% of the time or less and nursing care is required, and 4=bedridden and possibly requiring hospitalization.
§Medical history reporting has not routinely included ECOG; it is often judged from past medical history and presenting symptoms.
FIGO, International Federation of Gynecology and Obstetrics.